Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.

Exclusion Criteria

• •History of contraindications or hypersensitivity to radiprodil or any components of the formulations or history of hypersensitivity to warfarin, midazolam, digoxin, rosuvastatin, omeprazole, or vitamin K.
• •Female participants who are pregnant, breastfeeding, or have a positive pregnancy test at Screening.
• •History or presence of significant (in the opinion of the PI) cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, urologic, neurological, malignancy, psychiatric disease, or brain surgery or injury.
• •Any surgical or medical condition that, in the opinion of the PI, could interfere with the absorption, distribution, metabolism, or excretion of the drug.
• •History of any CS allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic seasonal allergies at time of dosing on Day 1).
• •History of illicit drug abuse or alcohol abuse use within 2 years of Screening.
• •History of suicide attempts or deliberate self-harm, or a score of 4 or 5 on ideation or any suicidal behavior on the C-SSRS.
• •Routine consumption of more than 2 units of alcoholic beverages per day or more than 14 units per week (a unit of alcohol is equivalent to 1 can of beer, 1 glass of wine, or the equivalent of 1 alcoholic drink).
• •Routine consumption of an average of more than five (5) 240 mL servings of coffee or other caffeinated beverages per day.
• •A positive test result for amphetamines, barbiturates, benzodiazepines, cocaine, methadone, methamphetamines, opiates, methylenedioxymethamphetamine, phencyclidine, tetrahydrocannabinol, cotinine, or alcohol at Screening or Day -1.
• •Use of marijuana (including prescribed marijuana) within 30 days of Day -1.
• •Use of tobacco-containing products and nicotine or nicotine containing products in the 2 months prior to Day 1.
• •Use of any IP and prescription drug within 30 days of Day -1 or within 5 half-lives whichever is longer.
• •Use of any over-the-counter (OTC) medication, including herbal products within the 14 days or 5 half-lives prior to dosing, whichever is longer.
• •Any vaccine within 7 days of Day -1.
• •Acute illness within 14 days of study Day 1.
• •Surgery within the past 90 days prior to Day 1.
• •Any CS ECG abnormality at Screening.
• •Received an IP in any clinical trial within 30 days of Day -1.
• •Women of childbearing potential using oral, injected or implanted hormonal contraception.